Finance

Lists
CABA:NASDAQ
Cabaletta Bio Inc
$1.95
0.00%
(0.00) 1D
$2.00
+2.56% (+0.05)
Pre-market
Closed: Oct 8, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CABA...
Mkt. cap
330.61M
Avg. vol.
5.82M
Volume
1.44K
52-wk high
$4.23
52-wk low
$1.83
EPS
-$1.57
Beta
3.48
Shares outstanding
169.54M
No. of employees
157
Mkt. cap
330.61M
Avg. vol.
5.82M
Volume
1.44K
52-wk high
$4.23
52-wk low
$1.83
EPS
-$1.57
Beta
3.48
Shares outstanding
169.54M
No. of employees
157
News stories
From web sources and news partners
About Cabaletta Bio Inc
CEO-
Employees157
Founded2017
HeadquartersPhiladelphia, Pennsylvania, United States
SectorBiotechnology
Websitecabalettabio.com
Analyst ratings
Based on 8 analysts giving stock ratings to CABA in the past 3 months
Strong buy
Buy
7
Hold
1
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for CABA in the last 3 months.
Highest
Current $1.95
$30.00 (+1,438.46%)
Average
$14.67 (+652.31%)
Lowest
$3.00 (+53.85%)
Analyst
Recommendation
Action
Price target
Projected
Date
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
$16.00
+720.5%
09/21/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
09/02/2026
Samantha Semenkow
Citi
Buy
Maintained
$10.00
+412.8%
09/01/2026
Unknown Analyst
Wells Fargo
Hold
Reiterated
$3.00
+53.8%
09/01/2026
Michael Ulz
Morgan Stanley
Buy
Reiterated
$13.00
+566.7%
08/17/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Reiterated
$30.00
+1,438.5%
08/14/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$16.00
+720.5%
08/13/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
08/13/2026
Roger Song
Jefferies
Buy
Maintained
$14.00
+617.9%
03/23/2026
Last report
Aug 13, 2026
Fiscal period
Q2 2026
-$0.34 / -$0.34
+0.76%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
39.82M
36.19M
37.35M
44.43M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.76M
6.42M
6.94M
7.59M
Operating expense
46.59M
42.61M
44.30M
52.02M
Total operating expenses
46.59M
42.61M
44.30M
52.02M
Operating income
-46.59M
-42.61M
-44.30M
-52.02M
Other non operating income
498.00K
-79.00K
341.00K
-84.00K
EBT including unusual items
-44.87M
-41.92M
-43.52M
-51.02M
EBT excluding unusual items
-44.87M
-41.92M
-43.52M
-51.02M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-44.87M
-41.92M
-43.52M
-51.02M
Net profit margin
-
-
-
-
Earnings per share
-0.44
-0.40
-0.39
-0.34
Interest and investment income
1.81M
1.33M
1.08M
1.60M
Interest expense
-584.00K
-555.00K
-636.00K
-517.00K
Net interest expenses
1.22M
771.00K
440.00K
1.09M
Depreciation and amortization charges
-
-
-
-
EBITDA
-46.24M
-42.26M
-43.96M
-51.65M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps